Short Interest in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Decreases By 24.6%

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 20,200 shares, a drop of 24.6% from the March 15th total of 26,800 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average trading volume of 18,700 shares, the short-interest ratio is presently 1.1 days.

PharmaCyte Biotech Trading Up 3.0 %

Shares of PMCB stock traded up $0.04 during trading hours on Friday, reaching $1.19. 13,357 shares of the company’s stock were exchanged, compared to its average volume of 21,539. The company has a market cap of $8.13 million, a price-to-earnings ratio of 2.24 and a beta of -0.53. PharmaCyte Biotech has a fifty-two week low of $1.03 and a fifty-two week high of $2.42. The stock’s 50 day moving average is $1.50 and its 200-day moving average is $1.62.

PharmaCyte Biotech (NASDAQ:PMCB) last released its quarterly earnings results on Monday, March 17th. The company reported ($0.10) EPS for the quarter.

PharmaCyte Biotech Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.